Jinan, China

Zhenming An

This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Qilu Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhenming An. Retrieved from https://idiyas.com/inventor/zhenming-an-bn6xrhry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhenming An: Innovator in Pharmaceutical Composition

Introduction

Zhenming An is a notable inventor based in Jinan, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions.

Latest Patents

Zhenming An holds a patent for a composition comprising aflibercept and a variant thereof, along with related methods and uses. This patent showcases his expertise in creating effective pharmaceutical solutions.

Career Highlights

He is currently employed at Qilu Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work at this esteemed company has positioned him as a key player in the pharmaceutical industry.

Collaborations

Zhenming An has collaborated with talented coworkers, including Daoyuan Li and Jianjun Zhang. Their combined efforts contribute to the innovative projects at Qilu Pharmaceutical Co., Ltd.

Conclusion

Zhenming An's contributions to pharmaceutical compositions highlight his role as an influential inventor in the industry. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…